Pfizer C-19 Problems And The Trial Is Under Investigation: Contract Company!

Some problems reported with the primary clinical trial examining Pfizer’s C-19 vaccine are probed, a contract company that participated in the research has confirmed.

Vestavia research Group worked on a free trial site in the fall of 2020. Brook Jackson worked for the company and talked to the British Medical Journal that the trial was riddled with problems, and among them was data falsification.

Jackson stated that she told the FDA about the problems she saw, and within hours she was fired.

Vestavia talked to the Epoch Times and stated it employed Jackson for two weeks one year ago. Lauren Foreman, the business development and communications director, sent an email that Ventavia investigated Jackson’s allegations.

“Vestavia takes research compliance, data integrity, and participant safety very seriously and stands behind its important work supporting the development of lifesaving vaccines and is conducting its investigation accordingly,” she said.

FDA knew about this problem.

“Although the agency cannot comment further at this time in this ongoing matter, FDA has full confidence in the data that were used to support the Pfizer-BioNTech COVID-19 vaccine authorization and the Comirnaty approval,” a spokeswoman told The Epoch Times in an email.

Vestavia was concentrated on a trial that brought her to EUA of the Pfizer shot. The FDA approved the vaccine to be applied to people.

Jackson worked on clinical trials for more than 15 years, said that she constantly raised concerns with her superiors about her statements. Later, she realized that they ignored her records, so she took photographs with her phone.

Jackson listed 12 concerns that she faced on September 25. She also alleged that Ventavia staff members were targeted by higher-ups for reporting problems.

The Epoch Time submitted a Freedom of Information Act request concerning Jackson’s email to the FDA and internal communications from the agency regarding the message.

The inspections were limited “because the study was ongoing, and the data required for verification and comparison were not yet available to the IND [investigational new drug],” an FDA officer wrote in a summary of the inspections.

The Epoch Times

Addison Wilson

A passionate teacher in English Language and Literature ready to give her best! Developing and implementing diverse curriculums covering a wide range of subjects. With my problem-solving skills, every job will be easily completed, so punctuation is my strength. Highly skilled at motivating students through positive encouragement and reinforcement of concepts via interactive classroom instruction and observation. My working style fits every personality type, so it makes me a great team player. I have completed numerous journalistic projects successfully, so digging for further information is my field. Fighter for freedom of speech! The truth must be revealed!

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Back to top button

Adblock Detected

For continue reading on the site please disable the Ad-block